Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women

Fertility and Sterility

Volumn 81, Issue 3, 2004, Pages 617-623

  Valdivia, Isabel ^a,b   Campodónico, Italo ^b   Tapia, Augusto ^b   Capetillo, María ^b   Espinoza, Arturo ^b   Lavín, Pablo ^b  

^a University of Chile ^*

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Apoptosis; Bcl 2; Hormone therapy; Ki67; Mammographic breast density; Proliferation; Tibolone

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; KI 67 ANTIGEN; PREMPAK PLUS; PROTEIN BCL 2; TIBOLONE;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST BIOPSY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MAMMOGRAPHY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

BIOLOGICAL MARKERS; BREAST; DRUG THERAPY, COMBINATION; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MAMMOGRAPHY; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; PROTO-ONCOGENE PROTEINS C-BCL-2; SINGLE-BLIND METHOD;

EID: 1642377145     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2003.07.041     Document Type: Article

References (35)

1. Kloosterboer H.J. Tibolone a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 76:2001;231-238.
2. Beral V., Bull D., Doll R., Key T., Peto R., Reeves G. Breast cancer and hormone replacement therapy; collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108.411 women without breast cancer. Lancet. 350:1997;1047-1059.
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 288:2002;321-333.
4. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc. 283:2000;485-491.
5. Ross R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy on breast cancer risk estrogen versus estrogen plus progestin. J Natl Cancer Inst. 92:2000;328-332.
6. Schairer C., Gail M., Byrne C., Rosenberg P.S., Sturgeon S.R., Brinton L.A., et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst. 91:1999;264-270.
7. Lundström E., Christow A., Kersemaekers W., Svane G., Azavedo E., Söderqvist G., et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol. 186:2002;717-722.
8. Speroff L. The meaning of mammographic breast density in users of postmenopausal hormone therapy. Maturitas. 41:2002;171-175.
9. Byrne C., Schairer C., Wolfe J., Parekh N., Salane M., Brinton L.A., et al. Mammographic features and breast cancer risk effects with time, age and menopause status. J Natl Cancer Inst. 87:1995;1622-1629.
10. Byng J.W., Yaffe M.J., Jong R.A., Shumak R.S., Lockwood G.A., Tritchler D.L., et al. Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics. 18:1998;1587-1598.
11. Hammar M., Christau S., Nathorst-Böös J., Rud T., Garre K. A double-blind randomized trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal complaints. Br J Obstet Gynaecol. 105:1998;904-911.
12. Valdivia I., Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin Drug Invest. 20:2000;101-107.
13. Gompel A., Somai S., Chaouat M., Kazem A., Kloosterboer H.J., Beusman I., et al. Hormonal regulation of apoptosis in breast cells and tissues. Steroids. 65:2000;593-598.
14. Van Dierendonck J.H., Keijzer R., van de Velde C.H.J., Cornelisse C.J. Nuclear distribution of the Ki67 antigen during the cell cycle comparison with growth fraction in human breast cancer cells. Cancer Res. 49:1989;2999-3006.
15. Hofseth L., Raafat A.M., Osuch J.R., Pathak D.R., Slomski C.A., Haslam S.Z. Hormone replacement therapy with estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab. 84:1999;4559-4565.
16. American College of Radiology. Breast imaging reporting and data system (BI-RADS). 2nd ed:1995;American College of Radiology, Reston, VA.
17. Wolfe J.N. Breast patterns as an index of risk for developing breast cancer. Am J Roentgenol. 126:1976;1130-1137.
18. Valdivia I., Ortega D. A one-year evaluation of mammary radiographic density (MxDx) changes with different HRTs regimens in climacteric women. Acta Obstet Gynecol Scand. 167:(Suppl 76):1997;101.
19. Erel C.T., Elter K., Akman C., Ersavasti G., Altug A., Seyisoglu H., et al. Mammographic changes in women receiving tibolone therapy. Fertil Steril. 69:1998;870-875.
20. Erel C.T., Esen G., Seyisoglu H., Elter K., Uras C., Ertungealp E., et al. Mammographic density increase in women receiving different hormone replacement regimens. Maturitas. 40:2001;151-157.
21. Colacurci N., Fornaro F., de Franciscis P., Palermo M., del Vecchio W. Effects of different types of hormone replacement therapy on mammographic density. Maturitas. 40:2001;159-164.
22. Egarter C., Eppel W., Vogel S., Wolf G. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas. 40:2001;165-171.
23. Sendag F., Terek M.C., Özsener S., Öztekin K. Mammographic density changes in postmenopausal women using tibolone therapy. Int J Gynecol Obstet. 74:2001;63-64.
24. von Schoultz B. The effects of tibolone and conventional HRT on breast cell proliferation and mammographic density. Climacteric. 5:(Suppl 1):2002;216.
25. Gompel A., Kandouz M., Siromachkova M., Lombet A., Thevenin D., Mimoun M., et al. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. Gynecol Endocrinol. 11:(Suppl 1):1997;77-79.
26. Kloosterboer H.J., Schoonen W.G.E.J., Deckers G.H., Klijn J.G.M. Effects of progestagens and Org OD14 in vitro and in vivo tumor models. J Steroid Biochem Mol Biol. 49:1994;311-318.
27. Gompel A., Chaouat M., Jacob D., et al. In vitro studies of tibolone in breast cells. Fertil Steril. 78:2002;351-359.
28. Kloosterboer HJ. New mechanisms of action for tibolone in breast cancer. In: Menopause. Hormones and cancer. Proceedings of the 2nd International Symposium of the Portuguese Menopause Society. 2002:37-47.
29. Chetrite G.S., Kloosterboer H.J., Philippe J.-C., Pasqualini J.P. Effect of Org OD 14 (Livial) and its metabolites on human estrogen sulfotransferase activity in the hormone-dependent MCF-7 and T-47D, and the hormone-independent MDA-MB-231, breast cancer cell lines. Anticancer Res. 19:1999;269-275.
30. Chetrite G.S., Kloosterboer H.J., Philippe J.-C., Pasqualini J.R. Effect of Org OD 14 (Livial) and its metabolites on 17β-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells. Anticancer Res. 19:1999;261-267.
31. de Gooyer M.E., Overklift Vaupel Kleyn G.T., Smits K.C., Ederveen A.G.H., Verheul H.A.M., Kloosterboer H.J. Tibolone a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol. 183:2001;55-62.
32. de Gooyer M.E., Oppers-Tiemissen H.M., Leysen D., Verheul H.A.M., Kloosterboer H.J. Tibolone is not converted by human aromatase to 7α-methyl-17α-ethynylestradiol (7α-MEE) analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS. Steroids. 68:2003;235-243.
33. Dören M., Röbig A., Coelingh Bennink H.J.T., Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril. 75:2001;554-559.
34. Isaksson E., von Schoultz E., Odlind V., Söderqvist G., Csemiczky G., Calström K., et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat. 65:2001;163-169.
35. Zhou J., Ng S. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J. 14:2000;1725-1730.